Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other financing activities (2016 - 2018)

Enanta Pharmaceuticals filings provide 7 years of Other financing activities readings, the most recent being -$5.5 million for Q2 2018.

  • On a quarterly basis, Other financing activities changed N/A to -$5.5 million in Q2 2018 year-over-year; TTM through Sep 2024 was -$5.5 million, a 68.06% decrease, with the full-year FY2023 number at $325000.0, changed N/A from a year prior.
  • Other financing activities hit -$5.5 million in Q2 2018 for Enanta Pharmaceuticals, down from $2.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.2 million in Q1 2018 to a low of -$5.5 million in Q2 2018.
  • Median Other financing activities over the past 5 years was -$2000.0 (2016), compared with a mean of -$222.22.
  • Biggest five-year swings in Other financing activities: plummeted 160.0% in 2015 and later soared 1767.65% in 2016.
  • Enanta Pharmaceuticals' Other financing activities stood at $1.9 million in 2014, then crashed by 100.16% to -$3000.0 in 2015, then soared by 33.33% to -$2000.0 in 2016, then tumbled by 12150.0% to -$245000.0 in 2017, then crashed by 2146.53% to -$5.5 million in 2018.
  • The last three reported values for Other financing activities were -$5.5 million (Q2 2018), $2.2 million (Q1 2018), and -$245000.0 (Q4 2017) per Business Quant data.